All eyes are on German conglomerate BayWa as it prepares to release its fourth-quarter figures for 2025 on March 26. This is no routine earnings announcement. The results are anticipated to fully quantify the substantial write-downs required for its renewable energy subsidiary, BayWa r.e., and will serve as a crucial test of creditor banks’ confidence in the company’s revised recovery strategy.
The existing turnaround plan has effectively collapsed. Of the total restructuring target of €4 billion set for achievement by 2028, only 33% has been met to date, leaving a staggering shortfall of approximately €2.7 billion. The company has already withdrawn its annual forecast for 2026.
A Restructuring Timeline Thrown into Disarray
Central to the crisis is the performance and valuation of BayWa r.e. A central pillar of the original rescue concept involved selling a 51% stake in this unit by the end of 2028, a move projected to generate roughly €1.7 billion in proceeds. That revenue stream is now unattainable.
A dramatic shift in U.S. energy policy under the Trump administration has fundamentally altered the market landscape. In January 2025, the government halted over $300 billion in subsidies for renewable energy projects. The following month, it revoked the classification of greenhouse gases as hazardous to public health. For BayWa r.e., which sold 534.7 megawatts in the U.S. market alone during 2024, these are not abstract political decisions. They directly impact the achievable sale price for the business. Consequently, the subsidiary is not expected to post positive operational results before 2027 at the earliest, pushing the planning horizon for the overall restructuring plan out to 2030.
Should investors sell immediately? Or is it worth buying BayWa?
Leadership Overhaul and Legal Scrutiny
Amid this financial recalibration, the company is undergoing a sweeping leadership change and facing legal scrutiny. CEO Frank Hiller is stepping down with immediate effect and will depart permanently by the end of July. Three supervisory board members, internally linked to the debt-fueled expansion strategy, will exit the board by the end of May. In a structural move aimed at addressing past lapses in oversight, the threshold for board approval on business transactions has been lowered from €200 million to €50 million.
Simultaneously, the Munich I public prosecutor’s office is conducting an investigation into allegations of breach of trust against several former executives. These include ex-CEO Marcus Pöllinger and longtime former chief executive Klaus Josef Lutz, whose private premises have been subject to searches. The presumption of innocence applies to all accused parties.
Seeking Stability Through Asset Sales and Bank Talks
To buy time for its new course, BayWa is negotiating a standstill agreement with core banks and major shareholders that would extend until autumn 2026. The balance sheet is receiving interim support from two partial transactions. The sale of the agricultural trading subsidiary Cefetra Group for €125 million will reduce bank liabilities by over €600 million through deconsolidation. Furthermore, the potential sale of New Zealand-based T&G Global, estimated to be worth around €300 million, is under consideration.
Tomorrow’s Q4 report will provide an initial milestone, but a complete picture of the restructuring status will only emerge with the publication of the full 2025 annual report. That comprehensive disclosure is likely to be delayed until the fourth quarter of 2026. Currently, the company’s shares trade in technically oversold territory with a Relative Strength Index (RSI) of 31.6, sitting approximately 14% below their 200-day moving average.
Ad
BayWa Stock: Buy or Sell?! New BayWa Analysis from March 20 delivers the answer:
The latest BayWa figures speak for themselves: Urgent action needed for BayWa investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 20.
BayWa: Buy or sell? Read more here...









